Aggrenox Journal Ad Improperly Suggests Superiority To Plavix, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The paper referenced in the ad is "a historically controlled trial that is inadequate to support a superiority claim," the FDA ad division letter states. The agency also cites the Aggrenox ad for omitting risk information.